We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for irinotecan (as sucrosofate) (Servier Laboratories (Aust) Pty Ltd)
Active ingredients
irinotecan (as sucrosofate)
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrated Injection
Indication
First-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV)
Therapeutic area
Oncology